Viscotin - Acetylcysteine | VetSafeCare.Com

Eff. Tab., Eff. Gran.

Viscotin

Acetylcysteine — UniMed UniHealth
600mg / 3 ml · 600mg / effervescent tablet · 200mg / sachet · 100mg / sachet

Alternatives

20

Routes

INH, PO

Presentations

4

Presentations

Nebuliser Solution · 600mg / 3 ml

3 ml

৳30

Effervescent Tablet · 600mg / effervescent tablet

1 effervescent tablet

৳20

Effervescent Granules · 200mg / sachet

1 effervescent granules

৳15

Effervescent Granules · 100mg / sachet

1 effervescent granules

৳10

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Cat

For acetaminophen toxicity:
a) A 2–3 hour wait between activated charcoal and PO administration of acetylcysteine (NAC) is necessary. Give NAC as an initial oral loading dose of 140 mg/kg (dilute to 5% in dextrose or sterile water), followed by 70 mg/kg PO four times daily (q6h) for 7 treatments. With ingestion of massive quantities, some authors suggest using a 280 mg/kg loading dose and continuing treatment for 12–17 doses. May also be given IV after diluting to 5% and given via slow IV over 15–20 minutes. Additional therapy may include IV fluids, blood or Oxyglobin®, ascorbic acid and SAMe. (Wismer 2006)

For phenol toxicity:
a) 140 mg/kg PO or IV initially, then 50 mg/kg q4h for 3 days. May be partially effective to reduce hepatic and renal injury. Resultant methemoglobinemia should be treated with ascorbic acid or methylene blue. (Dorman & Dye 2005) 

For adjunctive treatment of hepatic lipidosis (see also Carnitine):
a) Identify underlying cause of anorexia and provide a protein replete feline diet, give acetylcysteine (NAC) at 140 mg/kg IV over 20 minutes, then 70 mg/kg IV q12h; dilute 10% NAC with saline 1:4 and administer IV using a 0.25 micron filter; correct hypokalemia and hypophosphatemia, beware of electrolyte changes with re-feeding phenomenon (Center 2006)

Horse

To help break up chondroids in the gutteral pouch:
a) Instill 20% solution (Foreman 1999) In neonatal foals to break up meconium refractory to repeated enemas:
a) 8 grams in 20 g sodium bicarbonate in 200 mL water (pH of 7.6), give as enema as needed to effect (Freeman 1999)
b) With foal in lateral recumbency, insert a 30 french foley catheter with a 30 cc bulb for a retention enema. Using gravity flow, infuse slowly 100– 200 mL of 4% acetylcysteine solution and retain for 30–45 minutes. IV fluids and pain medication should be considered. Monitor for possible bladder distention. (Pusterla et al. 2003)

Dog

For acetaminophen (Paracetamol) toxicity:
a) A 2–3 hour wait between activated charcoal and PO administration of acetylcysteine (NAC) is necessary. Give NAC as an initial oral loading dose of 140 mg/kg (dilute to 5% in dextrose or sterile water), followed by 70 mg/kg PO four times daily (q6h) for 7 treatments. With ingestion of massive quantities, some authors suggest using a 280 mg/kg loading dose and continuing treatment for 12–17 doses. May also be given IV after diluting to 5% and given via slow IV over 15–20 minutes. Additional therapy may include IV fluids, blood or Oxyglobin®, ascorbic acid and SAMe. (Wismer 2006)
b) 150 mg/kg PO or IV initially, then 50 mg/kg q4h for 17 additional doses (Bailey 1986)
c) Loading dose of 140 mg/kg PO, then 70 mg/kg PO every 6 hours for 7 treatments (Grauer & Hjelle 1988)

For phenol toxicity:
a) 140 mg/kg PO or IV initially, then 50 mg/kg q4h for 3 days. May be partially effective to reduce hepatic and renal injury. Resultant methemoglobinemia should be treated with ascorbic acid or methylene blue. (Dorman & Dye 2005)

For hepatotoxicity secondary to xylitol poisoning:
a) Acetylcysteine at 140–280 mg/kg loading dose IV, PO; followed by 70 mg/kg four times daily; vitamin K (phytonadione) at 1.25–2.5 mg/kg PO twice daily; plasma, SAMe at 20 mg/kg/day PO; vitamin E at 100–400 Units twice daily PO; and silymarin 20–50 mg/kg/day PO. (Talcott 2008)

For degenerative myelopathy:
a) 25 mg/kg PO q8h for 2 weeks, then q8h every other day. The 20% solution should be diluted to 5% with chicken broth or suitable diluent.
Used in conjunction with aminocaproic acid (500 mg per dog PO q8h indefinitely). Other treatments may include prednisone (0.25–0.5 mg/kg PO daily for 10 days then every other day), Vitamin C (1000 mg PO q12h) and Vitamin E (1000 Units PO q12h). Note: No treatment has been shown to be effective in published trials. (Shell 2003)

Human

Effervescent tablet or Dispersible tablet: Adults and children above 6 years: One effervescent tablet of Acetylcysteine 600 mg a day (preferably in the evening). The duration of treatment should be 5 to 10 days in the acute treatment, whereas it may be continued in the chronic states for several months, according to the advice of the physician. Dissolve the tablets in a glass containing a small quantity of water, mixing it, if necessary, with a spoon. A palatable solution is thus obtained, which can be drunk directly from the glass.Effervescent Granules: Adults and children above 6 years: 1 sachet Acetylcysteine 200 mg or 2 sachets Acetylcysteine 100 mg, 2-3 times a day. Children (2-6 years of age): 1 sachet Acetylcysteine 100 mg from 2 to 4 times a day, according to the age. The duration of treatment should be 5 to 10 days in the acute treatment, whereas it may be continued in the chronic states for several months, according to the advice of the physician.Dissolve the contents of the sachets in a glass containing a small quantity of water; mixing it, if necessary, with a spoon. A palatable solution is thus obtained, which can be drunk directly from the glass.Nebuliser Solution: The 20% solution may be diluted to a lesser concentration with either Sodium Chloride for injection, Sodium Chloride for inhalation, sterile water for injection, or sterile water for inhalation. Adult: 5-10 ml of 10% or 20% solution by Nebuliser every 6-8 hr PRN. Children: 1-11 months: 1-2 ml of 20% or 2-4 ml of 10% solution by Nebuliser every 6-8 hr PRN. 12 months-11 years: 3-5 ml of 20% or 6-10 ml of 10% solution by Nebuliser every 6-8 hr PRN. Below 12 years: 5-10 ml of 10/20% solution by Nebuliser every 6-8 hr PRN. ** Diagnostic Bronchograms: 1-2 ml of 20% or 2-4 ml of 10% solution 2-3 times by Nebulisation or by instillation intratracheally prior to procedure.** Nebulisation tent or croupette: This form of administration requires very large volumes of the solution, occasionally as much as 300 ml during a single treatment period. If a tent or croupette must be used, the recommended dose is the volume of acetylcysteine (using 20%) that will maintain a very heavy mist in the tent or croupette for the desired period. Administration for intermittent or continuous prolonged periods, including overnight, may be desirable.** Direct Instillation: When used by direct instillation, 1-2 ml of a 20% solution may be given as often as every hour. When used for the routine nursing care of patients with tracheostomy, 1-2 ml of a 20% solution may be given every 1-4 hours by instillation into the tracheostomy.

Clinical notes

Applications:
  • Tuberculosis
Indication Notes:
Acetylcysteine is indicated as an adjuvant treatment in certain clinical condition characterized by the presence of thick and viscous mucoid or mucopurulent secretions such as: Chronic bronchopulmonary diseases (chronic obstructive pulmonary disease, emphysema with bronchitis, chronic asthmatic bronchitis ... Read moreAcetylcysteine is indicated as an adjuvant treatment in certain clinical condition characterized by the presence of thick and viscous mucoid or mucopurulent secretions such as: Chronic bronchopulmonary diseases (chronic obstructive pulmonary disease, emphysema with bronchitis, chronic asthmatic bronchitis, bronchiectasis); Acute bronchopulmonary diseases (asthma with bronchial mucus plugging, bronchitis, bronchopneumonia, tracheobronchitis, bronchiolitis, pulmonary complications of cystic fibrosis, pulmonary complications associated with surgery).
Avoid In:

N/A

Contraindication Notes:
Known hypersensitivity to Acetylcysteine. Acetylcysteine contains aspartame, thus it is contraindicated in patients suffering from phenylketonuria.
Acetylcysteine is a mucolytic agent that reduces the viscosity of secretions probably by the splitting of disulphide bonds in mucoproteins. Moreover it gives antisecretory effect. These results in clearing of respiratory ducts and facilitate breathing. Acetylcysteine also has anti-oxidant properties by reacting with free radicals and also by serving as a precursor to glutathione, which is an important intra and extra-cellular antioxidant. By providing anti-oxidant action, it neutralizes exogenous and endogenous oxidants, which in fact act as pathogens in respiratory inflammations.
The thiol group of Acetylcysteine can reduce the efficacy of certain antibiotics such as ampicillin, tetracycline, macrolides, cephalosporins, aminoglycosides and amphotericin. Concomitant use of Acetylcysteine and amoxicillin will increase the level of the antibiotic in tissues. It is, therefore, advisable to use the two medicines 2 hours apart from each other. Acetylcysteine can increase the inhibitory effect of thrombocyte aggregation and vasodialation by nitroglycerine.
Like all medicines, Acetylcysteine can cause side effects, although not everybody gets them. In very rare cases, severe immune reactions may occur such as anaphylactic shock and severe skin reaction. In rare cases the oral administration can be followed by shortness of breath, upset stomach and bronchospasm. The most frequent side effects are headache, increased heart rate, stomatitis, pruritus, urticaria, nausea, vomiting, abdominal pain, fever, decrease in the blood pressure, diarrhoea and noises in the ears.
Overdose of Acetylcysteine may cause nausea, vomiting or diarrhoea.
In case of pregnancy & lactation the medicine should be taken consulting physician or pharmacist.
Patients suffering from bronchial asthma must be strictly controlled during the therapy; should bronchospasm occur, the treatment must immediately be suspended. Caution should be taken in patients suffering from or with a history of peptic ulcer. As Viscotin contains sodium (156.9mg per dose) this has to be taken into consideration by patients on a controlled sodium diet. The possible presence of a sulphureous odor does not indicate an alteration of the product but is a characteristic of the active ingredient contained in this preparation. It is preferable not to mix other drugs with the Viscotin solution.